BBIO Q1 2025 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$117M-44.8% YoY

Gross Profit

$114M97.7% margin

Operating Income

-$104M-89.5% margin

Net Income

-$167M-143.5% margin

EPS (Diluted)

$-0.88

QoQ Revenue Growth

+1882.9%

Cash Flow

Operating Cash Flow

-$199M

Free Cash Flow

-$201M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$882M

Total Liabilities

$2.5B

Stockholders' Equity

-$1.6B

Cash & Equivalents

$541M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$117M	$211M	-44.8%
Gross Profit	$114M	$211M	-45.9%
Operating Income	-$104M	$343,000	-30529.2%
Net Income	-$167M	-$35M	-375.4%

Revenue Segments

Net Product Revenue

$37M100%